Sign inSubscribe

target directory

anemia in chronic kidney disease clinical trial intelligence

Trials are included when the normalized target field matches this target directory. Full protocol, result, eligibility and IP analysis is available inside the premium workspace.

Validated reports

1

Directory type

target

Association rule

normalized field

NCT02879305
Source recordAI-normalized

A Phase 3 Randomized, Open-label (Sponsor-blind), Active-controlled, Parallel-group, Multi-center, Event Driven Study in Dialysis Subjects With Anemia Associated With Chronic Kidney Disease to Evaluate the Safety and Efficacy of Daprodustat Compared to Recombinant Human Erythropoietin, Following a Switch From Erythropoietin-stimulating Agents

The ASCEND-D trial evaluated the safety and efficacy of daprodustat, a novel prolyl hydroxylase inhibitor, in treating anemia associated with chronic kidney disease (CKD) in dialysis patients. Conducted by GlaxoSmithKline, the study involved 2,964 participants across 431 centers in 35 countries, comparing daprodustat to recombinant human erythropoietin (rhEPO).

AI analysis

Indication: Anaemia

Modality: small molecule

Target: Anemia in Chronic Kidney Disease

Sponsor: GlaxoSmithKline

Source URL: ClinicalTrials.gov

Source updated: Dec 03, 2021

Ingested: May 30, 2026

Model: trialsignal-ai-v1

Validation: validated

Matched by target_normalized: Anemia in Chronic Kidney Disease

View original source fields

Condition raw: Anaemia

Condition normalized: Anaemia

Modality raw: Anaemia

Modality normalized: small molecule

Target raw: Anemia in Chronic Kidney Disease

Target normalized: Anemia in Chronic Kidney Disease

Open report